Assess Structural Damage in Rheumatoid Arthritis Using Biomarkers and Radiography
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01476956|
Recruitment Status : Unknown
Verified July 2018 by Canadian Research & Education in Arthritis.
Recruitment status was: Active, not recruiting
First Posted : November 22, 2011
Last Update Posted : July 17, 2018
Recruited patients will include those about to begin Disease-Modifying Antirheumatic Drug) DMARD therapy or about to change DMARD therapy.
Disease activity will be monitored systematically every 3 months by the Disease Activity Score.
Changes in standard DMARD and/or anti-Tumor Necrosis Factor α (anti-TNFα) therapy will be made according to specific recommendations for patients receiving these therapies.
Biomarker samples will be collected every 3 months and prior to change in DMARD and/or anti-TNF therapy as defined below. A blood sample (40 ml) for serum will be taken for biomarker studies and processed according to the international committee of Outcome Measures in Rheumatology (OMERACT) recommendations for the minimal handling of biomarker samples. A urine sample (20 ml) will also be taken and processed as for serum.
Radiography (X-rays) will be conducted every 6 months (baseline, 6, 12, 18, 24 months).
Patients will be followed for 2 years.
|Condition or disease||Intervention/treatment|
|Rheumatoid Arthritis||Other: Observational study|
|Study Type :||Observational|
|Estimated Enrollment :||600 participants|
|Official Title:||Prospective Validation of Soluble Biomarkers as Predictors of Structural Damage in Rheumatoid Arthritis|
|Actual Study Start Date :||October 2011|
|Estimated Primary Completion Date :||December 31, 2018|
|Estimated Study Completion Date :||December 2019|
Other: Observational study
RA patients on standard DMARD therapy
- To determine the independent predictive validity of several soluble biomarkers for predicting structural damage in Rheumatoid Arthritis (RA). [ Time Frame: 24 Months ]
- To establish which modifiable clinical and laboratory predictors used in routine practice individually and in combination, have the strongest and the most consistent association with change in radiographic damage in patients on standard RA therapy. [ Time Frame: 24 Months ]
Biospecimen Retention: Samples Without DNA
- whole blood/serum
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01476956
|Study Director:||Walter P. Maksymowych, MD||CaRE Arthritis|